Research

Hormonal

Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in East Asian adults with overweight or obesity, specifically enhancing physical functioning, psychosocial well-being, and total quality of life scores compared to placebo.

If you are an East Asian adult with overweight or obesity, once-weekly semaglutide 2.4 mg, combined with a modest 500-kcal daily calorie deficit and 150 minutes of weekly physical activity, has been shown to significantly improve your physical functioning, psychosocial well-being, and overall quality of life compared to placebo. This treatment helps you feel better in social situations and perform daily activities more comfortably.

GoodSupportsHIGH confidence
Treatment with semaglutide 2.4 mg improved aspects of WRQOL and HRQOL in people from East Asia with overweight/obesity.
Ronette L. Kolotkin et al. · Clinical Obesity · 2023

Why this rating

Randomized controlled trial with a clear treatment arm, though the sample size (n=401) is moderate and multiplicity was not controlled for.

Source

Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the <scp>STEP</scp> 6 trial

Ronette L. Kolotkin et al. · Clinical Obesity · 2023

DOI 10.1111/cob.12589

rct · n=401Cited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →